Monday, December 12, 2016 1:40:18 AM
Support/Resistance Levels Price Key Turning Points
52-Week High 104.79
94.50 Price Crosses 9-18 Day Moving Average
91.82 38.2% Retracement From 52 Week High
91.01 Price Crosses 9-40 Day Moving Average
14 Day RSI at 80% 88.55
87.81 50% Retracement From 52 Week High/Low
84.66 Price Crosses 18-40 Day Moving Average
83.80 38.2% Retracement From 52 Week Low
13-Week High 82.07
14 Day RSI at 70% 80.50
1-Month High 80.00
77.78 38.2% Retracement From 13 Week High
76.50 38.2% Retracement From 4 Week High
76.45 50% Retracement From 13 Week High/Low
76.35 Price Crosses 9 Day Moving Average Stalls
75.42 50% Retracement From 4 Week High/Low
75.12 38.2% Retracement From 13 Week Low
74.87 Price Crosses 18 Day Moving Average Stalls
74.61 14-3 Day Raw Stochastic at 80%
74.33 38.2% Retracement From 4 Week Low
74.28 Price Crosses 40 Day Moving Average
74.13 14-3 Day Raw Stochastic at 70%
74.06 14 Day RSI at 50%
73.95 Price Crosses 18 Day Moving Average
Pivot Point 2nd Level Resistance 73.77
Pivot Point 1st Resistance Point 73.24
73.19 14-3 Day Raw Stochastic at 50%
High 73.13 High
72.75 Price Crosses 40 Day Moving Average Stalls
Last 72.70 Last
72.66 Price Crosses 9 Day Moving Average
72.59 Pivot Point
72.27 3-10 Day MACD Oscillator Stalls
72.25 14-3 Day Raw Stochastic at 30%
72.14 3-10-16 Day MACD Moving Average Stalls
Pivot Point 1st Support Point 72.06
Previous Close 72.02 Previous Close
Low 71.95 Low
71.77 14-3 Day Raw Stochastic at 20%
Pivot Point 2nd Support Point 71.41
71.41 14 Day %k Stochastic Stalls
71.11 14 Day %d Stochastic Stalls
13-Week Low 70.83
1-Month Low 70.83
52-Week Low 70.83
14 Day RSI at 30% 69.44
14 Day RSI at 20% 63.67
Recent GILD News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 11:07:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 09:08:41 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:45:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/12/2024 08:43:35 PM
- Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial • Business Wire • 09/12/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:41:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:38:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:33:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:23:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/11/2024 11:20:53 PM
- Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies • Business Wire • 09/10/2024 12:00:00 PM
- Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer • Business Wire • 09/05/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/29/2024 07:23:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/28/2024 08:18:35 PM
- Gilead Sciences to Present at Upcoming Investor Conferences • Business Wire • 08/21/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/14/2024 06:23:44 PM
- Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA • Business Wire • 08/14/2024 05:59:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/13/2024 08:27:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 08:22:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:17:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 08:06:06 PM
- Gilead Sciences Announces Second Quarter 2024 Financial Results • Business Wire • 08/08/2024 08:02:00 PM
- U.S. Index Futures Drop, Signaling Ongoing Market Volatility; Oil Prices Stall • IH Market News • 08/08/2024 09:55:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/26/2024 09:28:51 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM